Amyloid precursors and amyloidosis in inflammatory arthritis

Current Opinion in Rheumatology

Volumn 13, Issue 1, 2001, Pages 67-73

  Cunnane, Gaye ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; AMYLOID PRECURSOR PROTEIN; COLCHICINE; DIMETHYL SULFOXIDE; HIGH DENSITY LIPOPROTEIN;

ACUTE PHASE RESPONSE; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTHRITIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; INFECTION; MULTIGENE FAMILY; NEOPLASM; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SYNOVITIS;

AMYLOIDOSIS; ARTHRITIS, RHEUMATOID; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, HDL3; SERUM AMYLOID A PROTEIN;

EID: 0035164775     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200101000-00011     Document Type: Review

References (92)

1. Amyloid precursors and amyloidosis in rheumatoid arthritis
2. The amyloidoses
3. The epidemiology of AL and AA amyloidosis
4. Clinical and therapeutic aspects of AA amyloidosis
5. Amyloidosis
6. Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo
7. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein
8. Human serum amyloid A (SAA) protein: A prominent acute phase reactant for clinical practice
9. Serum amyloid A changes high density lipoproteins cellular affinity: A clue to serum amyloid A's principal function
10. Human serum amyloid A genes are expressed in monocyte/macrophage cell lines
11. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: Implications for serum amyloid A function
12. Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain
13. Serum amyloid A in Alzheimer's disease brain is predominantly localized to myelin sheaths and axonal membrane
14. Local expression of acute phase serum amyloid A in rheumatoid arthritis tissues and cells
15. Acute phase serum amyloid A production by rheumatoid arthritis synovial tissue
16. Widespread expression of serum amyloid A in histologically normal human tissues: Predominant localization to the epithelium
17. Regulation of cytokines, cytokine inhibitors and acute phase proteins following anti-TNFα therapy in rheumatoid arthritis
18. The kinetics and magnitude of the synergistic activation of the serum amyloid A promoter by IL-1β and IL-6 is determined by the order of cytokine addition
19. Synergism of interleukin 1 and interleukin 6 induces serum amyloid A production while depressing fibrinogen: A quantitative analysis
20. Induction of human serum amyloid A in Hep 3B cells by IL-6 and IL-1 beta involves both transcriptional and post-transcriptional mechanisms
21. The role of NF kappa B and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6
22. Synergistic induction of mouse serum amyloid A3 promotor by the inflammatory mediators, IL- and IL-6
23. Activation of Sp1 and its functional co-operation with serum amyloid A-activating sequence binding factor in synoviocyte cells trigger synergistic action of interleukin-1 and interleukin-6 in serum amyloid A gene expression
24. Regulation of serum amyloid A protein expression during the acute phase response
25. Persistent expression of serum amyloid A during experimentally induced chronic inflammatory condition in rabbit involves differential activation of SAF, NFκB and C/EBP transcription factors
26. The sphingomyelin-ceramide pathway participates in cytokine regulation of C-reactive protein and serum amyloid A, but not α-rinogen
27. Mechanism of minimally modified LDL-mediated induction of serum amyloid A gene in monocyte/macrophage cells
28. Posttranscriptional regulation of acute phase serum amyloid A2 espression by the 5′- and 3′-untranslated regions of its mRNA
29. Hepatic catabolism of serum amyloid A during an acute phase response and chronic inflammation
30. Purified human I kappa B can rapidly dissociate the complex of the NF-kappa B transcription factor with its cognate DNA
31. I kappa B alpha deficiency results in a sustained NF-kappa B response and severe widespread dermatitis in mice
32. Constitutive NF-kappa B activation, enhanced granulopoieais, and neonatal lethality in I kappa B alpha-deficient mice
33. YY1 represses rat serum amyloid A1 gene transcription and is antagonized by NP-kappa B during acute-phase response
34. Antioxidant and redox regulation of gene transcription
35. Expression of a biologically active recombinant mouse IL-1 receptor antagonist and its use in vivo to modulate aspects of the acute phase response
36. Differential regulation of IL-6 gene transcription and expression by IL-4 and IL-10 in human monocytic cell lines
37. A cell culture system for the study of amyloid pathogenesis
38. Immunolocalization of serum amyloid A and AA amyloid in lysosomes in murine monocytoid cells: Confocal and immunogold electron microscopic studies
39. Apolipoprotein serum amyloid A down-regulates smooth muscle cell lipid biosynthesis
40. Serum amyloid A binds specific extracellular matrix glycoproteins and induces the adhesion of resting CD4+ T cells
41. Serum amyloid A is a chemoattractant: Induction of migration, adhesion and tissue infiltration of monocytes and polymorphonuclear leukocytes
42. Serum amyloid A is a chemotactic agonist at FPR2, a low affinity N-formylpeptide receptor on mouse neutrophils
43. Serum amyloid A induces chemotaxis of human mast cells by activating a pertussis toxin-sensitive signal transduction pathway
44. Serum amyloid A, and acute phase protein, inhibits platelet activation
45. Serum amyloid A is an activator of PMN antimicrobial functions: Induction of degranulation, phagocytosis and enhancement of anti-Candida activity
46. Human serum amyloid A has cytokine-like properties
47. A novel function of serum amyloid A: A potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1 beta and interleukin-8 by human blood neutrophil
48. Serum amyloid A-derived peptides, present in human rheumatic synovial fluids, induce the secretion of interferon-gamma by human CD4+ T lymphocytes
49. Serum amyloid A (SAA3) produced by rabbit synovial fibroblasts treated with phorbol esters or interleukin 1 induces synthesis of collagenase and is neutralized with specific antiserum
50. Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts
51. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
52. Enhanced inflammatory response in patients with preinfarction angina
53. Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI IIA substudy
54. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
55. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men
56. Expression and function of serum amyloid A, a major acute-phase protein in normal and disease states
57. Role of serum amyloid A during metabolism of acute phase HDL by macrophages
58. Amino terminal region of acute phase, but not constitutive serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells
59. Serum amyloid A in the assessment of early inflammatory arthritis
60. Serum amyloid A - An indicator of inflammation in ankylosing spondylitis
61. Behcet's disease and AA-type amyloidosis
62. Amyloidosis in mixed connective tissue disease
63. Serum amyloid A concentrations in giant cell arteritis and polymyalgia rheumatica
64. Secondary amyloidosis associated with giant cell arteritis/polymyalgia rheumatica
65. Activation of the cytokine network in Familial Mediterranean Fever
66. The relation between familial Mediterranean fever and amyloidosis
67. Inflammation-mediated rheumatic diseases and atherosclerosis
68. Comparison of serum amyloid A and C-reactive protein as indicators of lung inflammation in corticosteroid treated and non-corticosteroid treated cystic fibrosis patients
69. Serum amyloid A protein in acute viral infections
70. C-reactive protein and serum amyloid A in neonatal infections
71. Acute phase proteins or tumour markers: The role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases
72. Serum amyloid A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis
73. Serum amyloid A (SAA): An acute phase protein and apolipoprotein
74. Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis
75. Major acute phase reactant synthesis during chronic inflammation in amyloid-susceptible and -resistant mouse strains
76. Amyloid fibrillogenesis: Themes and variations
77. The heparin/heparan sulfate-binding site on aposerum amyloid A
78. In vitro degradation of serum amyloid A by cathepsin D and other acid proteases: Possible protection against amyloid fibril formation
79. Elastase-type proteases on the surface of human blood monocytes: Possible role in amyloid formation
80. Amyloid enhancing factor-loaded macrophages in amyloid fibril formation
81. Diet, amyloid enhancing factor (AEF) and amyloidogenesis: An hypothesis
82. Human amyloid P component: An elastase inhibitor
83. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis
84. Amyloidosis in rheumatoid arthritis: Clinical study of 124 histologically proven cases
85. Assessment of relative sensitivities of noninvasive tests for cardiac amyloidosis in documented cardiac amyloidosis
86. Gastrointestinal manifestations of amyloidosis
87. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression
88. Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatic disease
89. Regression of nephrotic syndrome due to amyloidosis secondary to familial Mediterranean fever following colchicine treatment
90. A fish oil diet retards experimental amyloidosis, modulates lymphocyte function and decreases macrophage arachidonate metabolism in mice
91. Arresting amyloidosis in vivo using small molecule anionic sulphonates or sulphates: Implications for Alzheimer's disease
92. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene